Filana Therapeutics, Inc. (FLNA) company profile
Close on Nov 20, 2026Market cap $30.98MP/E –Yield –
About Filana Therapeutics
Pharmaceutical Preparations, SIC 2834
Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system disorders. The company's lead drug candidate is simufilam, a proprietary oral small molecule designed to modulate filamin A protein activity. Filana is studying simufilam specifically for the treatment of tuberous sclerosis complex-related epilepsy, a genetic condition that causes non-malignant tumors and frequent treatment-resistant seizures. While the company operates in pharmaceutical research and development, its prospective end users are individuals affected by central nervous system conditions and tuberous sclerosis complex.
The company is headquartered in Austin, Texas. Filana maintains exclusive worldwide rights and patent protections for simufilam across jurisdictions including the United States, Europe, Australia, Israel, Canada, and Japan. The company does not own or lease manufacturing facilities, choosing instead to outsource development, formulation, and drug substance production to third-party contract manufacturers such as Evonik Corporation. Research collaborations, preclinical evaluations, and patent licensing agreements have also been established with academic and scientific organizations.
Summary of the business section of Filana Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Filana Therapeutics, Inc.
- Founded
- 1998
- Headquarters
- Austin, TX
- Address
- 6801 N Capital Of Texas Highway, Building 1; Suite 300 78731
- Phone
- (512) 501-2444
- Website
- www.cassavasciences.com
- Employees
- 17, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Austin, Texas
Stock & identifiers
- Ticker
- FLNA
- Former tickers
- SAVA until Oct 20, 2026; PTIE until Mar 29, 2019
- Exchange
- Nasdaq
- IPO date
- Jul 14, 2000
- Shares outstanding
- 48M, Jul 27, 2026
- Public float
- $87.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-7 reverse, May 10, 2017
- SEC CIK
- 1069530
- CUSIP
- 14817C107
- ISIN
- US14817C1071
- FIGI
- BBG000BK9YW3
- Share class FIGI
- BBG001SCKXX9
- LEI
- 529900XA0UG5JXABYF08
- EIN
- 91-1911336
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Richard Barry | President & CEO, Director | 1,955,947 |
| Eric Schoen | Chief Financial Officer | 31,500 |
| Robert Christopher Cook | Chief Operating& Legal Officer | 135,300 |
| Freda Nassif | Chief Business Officer | – |
| James William Kupiec | Chief Medical Officer | 0 |
| Robert Eugene Anderson Jr | Director | 27,600 |
| Jill M. Quigley | Director | – |
| Dawn Carter Bir | Director | – |
| Patrick J. Md Scannon Phd | Director | 1,000 |
| Pierre Gravier | Director | – |
| Robert Z. Gussin | Director | 10,617 |
| Claude Nicaise | Director | – |
| Donnell Michael J. O | Director | 65,812 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr Barbier | $0 | $0 | $824.50K | $7 | – |
| FY2025 Mr Barry | $1.52M | $1.33M | $824.50K | $7 | – |
| FY2024 Former PEO | $3.69M | -$1.01M | $3.58M | $8 | – |
| FY2024 Mr Barbier | $3.69M | -$1.01M | $3.58M | $8 | – |
| FY2024 Mr Barry | $16.73M | $1.78M | $3.58M | $8 | – |
| FY2023 | $6.26M | $7.56M | $2.41M | $76 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Richard J. Barry President and Chief Executive Officer | $675.00K | $355.00K | $490.04K | $1.52M | -91% |
| R. Christopher Cook Chief Operating and Legal Officer (2) | $463.98K | $215.00K | $140.01K | $818.99K | -75% |
| Eric J. Schoen Chief Financial Officer | $475.00K | $215.00K | $140.01K | $830.01K | -78% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 17 full-time employees and 3 employees who devote a portion of their professional time to the Company.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 18, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 19, 2026 | Name change | Name changed from CASSAVA SCIENCES INC to Filana Therapeutics, Inc. |
| Aug 8, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 3, 2024 | Delisting | Notice of delisting from exchange (Form 25) |
| Jan 3, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 25, 2019 | Name change | Name changed from PAIN THERAPEUTICS INC to CASSAVA SCIENCES INC |
| May 1, 2018 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 16, 2018 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 18, 2016 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
See a number that looks wrong?